NCT04823715已完成不适用
Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 163
- 试验地点
- 1
- 主要终点
- Disease-free survival of the patient after start of treatment
研究概览
简要总结
Patients with non-metastatic unresectable hepatocellular carcinoma
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years of age
- •Histologically proven hepatocellular carcinoma or proven according to radiological and biochemical criteria (EASL-AASLD) in cirrhotic patients
- •Child-Pugh class A
- •Absence of truncular or lobar portal vein invasion, or suprahepatic vein invasion
排除标准
- •Uncontrolled replication of hepatitis B virus
- •Transplanted liver
- •Previous abdominal irradiation
- •Previous treatment of HCC with systemic therapy, or with surgical resection in the 2 previous years
- •Metastatic illness
结局指标
主要结局
Disease-free survival of the patient after start of treatment
时间窗: Within 10 years after the treatment (surgical resection or TACE)
Disease-Free Survival (DFS) defined as the time (in months) between the treatment (surgical resection or TACE) and the diagnostic of local, locoregional or distant recurrence, or date of death from any cause; patients who are alive or lost to follow-up at the time of the analysis will be censored on the last follow-up date; patients who have received a liver transplant for non-carcinologic reason will be censored on the date of transplantation.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT06232759Guangxi Medical University56
终止
2 期
Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular CarcinomaLiver NeoplasmsNCT02470533Erasmus Medical Center100
已完成
2 期
Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +AxitinibHepatocellular CarcinomaNCT01352728Chinese University of Hong Kong50
招募中
不适用
TACE-HAIC vs. HAIC for Potentially Resectable HCCPotentially ResectionHepatocellular CarcinomaNCT03591705Sun Yat-sen University240
招募中
2 期
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical TrialHepatocellular CarcinomaNCT05751343Sun Yat-sen University55
